by Dana-Farber Cancer Institute Credit: Unsplash/CC0 Public Domain Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of phase 3 clinical trial of adjuvant immunotherapy in this patient population. Patients who were treated for nearly a year with pembrolizumab experienced...
